News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
MT Newswires Deals and strategy
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
* Immuron press release [https://seekingalpha.com/pr/20633267-immuron-reports-fy26-preliminary-results] (IMRN [https://seekingalpha.com/symbol/IMRN]): FY record sales of A$7.7 million, growth of 6% on pcp. * Net loss of A$3.8M, improvement of A$1.4M. MORE ON IMMURON * Immuron Limited (IMRN) Presents at 95th Emerging Growth Conference - Slideshow [https://seekingalpha.com/article/4938454-immuron-limited-imrn-presents-at-95th-emerging-growth-conference-slideshow] * Seeking โฆ
Immuron (ASX:IMC) announced its preliminary financial results for fiscal year 2026, reporting a 6% increase in global sales revenue to $7.7 million. The company also saw an improved net loss of $3.8 million, a $1.4 million reduction from the previous year. Immuron achieved key โฆ
Immuron Limited (ASX:IMC) announced a 5.9% increase in revenue to $7,713,601 for the year ended June 30, 2026, primarily driven by Travelanยฎ sales in Australia and North America. The company also significantly reduced its net loss after tax by 26.4% to $3,838,699. Immuron's cash โฆ
Immuron Ltd (IMRN) reported a 6% increase in global sales revenue to A$7.7 million for FY2026, driven by strong performance in Australia and the U.S. The company is strategically repositioning itself as a commercially focused biopharmaceutical business, relying on over-the-counter products like Travelan and โฆ
Immuron Limited's CEO, Steven Lydeamore, is scheduled to present at the Emerging Growth Conference on August 19, 2026, from 4:25pm to 4:35pm U.S. Eastern Time. The Australian biopharmaceutical company, dual-listed on ASX (IMC) and NASDAQ (IMRN), specializes in developing orally delivered targeted polyclonal antibodies โฆ
Immuron Limited announced that CEO Steven Lydeamore will present virtually at the Emerging Growth Conference on August 19, 2026. The company highlighted its orally delivered targeted polyclonal antibody platform, featuring its lead product Travelanยฎ for travelers' diarrhea, pipeline asset IMM-529 for C. difficile infection, โฆ
Immuron Limited (ASX:IMC) announced that its CEO, Steven Lydeamore, will deliver a virtual presentation at the Emerging Growth Conference on August 19, 2026, from 4:25 pm to 4:35 pm U.S. Eastern Time. The company, an Australian biopharmaceutical firm, specializes in orally delivered targeted polyclonal โฆ
Immuron Limited CEO Steven Lydeamore will present virtually at the Emerging Growth Conference on August 19, 2026, from 4:25pm to 4:35pm U.S. Eastern Time. The biopharmaceutical company, listed on both ASX and NASDAQ, focuses on orally delivered targeted polyclonal antibodies for infectious diseases. Immuron's โฆ
This article provides an in-depth look at Immuron Ltd (IMRN) cash flow statements, including operating, investing, and financing cash flows, both quarterly and annually. It highlights the company's negative operating cash flow and free cash flow in the latest fiscal period, alongside explanations of โฆ
This TradingKey analysis of Immuron Ltd (IMRN) focuses on its stock performance and proprietary stock score. The article details how TradingKey generates its comprehensive stock score based on 34 indicators across six dimensions: financial health, company profile, earnings forecasts, price momentum, institutional confidence, and โฆ
Immuron Limited's CEO, Steven Lydeamore, presented at the TechKnow Invest Roadshow, highlighting the company's progress in oral polyclonal antibody therapies. The presentation covered their commercial product Travelanยฎ for travelers' diarrhea, the investigational drug IMM-529 for recurrent Clostridioides difficile infection, and the distributed product ProIBSยฎ โฆ
Immuron Limited shared an investor update detailing FY26 sales, cash position, and plans for its clinical assets. The company reported global sales revenue of A$7.7 million for FY26, a 6% increase from the previous year, and maintains a strong cash balance of A$10.0 million โฆ
This article focuses on the institutional confidence in Immuron Ltd (IMRN), detailing the shareholding and activity of various financial institutions. Key institutions like Morgan Stanley & Co. LLC and Citadel Advisors LLC significantly increased their holdings, while others like XTX Markets LLC and Rhumbline โฆ
This article provides an earnings forecast for Immuron Ltd (IMRN), indicating a "Buy" rating based on one analyst's assessment. The target price for IMRN is set at USD 5.00, representing a significant upside. The report includes current market data and a peer comparison, but โฆ
This article provides a risk assessment for Immuron Ltd (IMRN), focusing on its volatility, financial risk, and investment risk based on various metrics. It details the company's market performance, including daily returns, drawdowns, Sharpe Ratios, and different measures of volatility and liquidity. The data โฆ
This article provides a technical analysis of Immuron Ltd (IMRN), focusing on various indicators and moving averages. It presents a summary of "Sell," "Neutral," and "Buy" signals from nine common technical indicators and six moving averages. The analysis concludes with a "Neutral" signal based โฆ
This article provides a revenue breakdown for Immuron Ltd (IMRN) for Fiscal Year 2023, showcasing its business segments and regional contributions. Travelan accounts for the vast majority of revenue at 96.68%, with Protectyn making up the remaining 3.32%. Geographically, Australia generates 64.31% of revenue, โฆ
This article provides details on the dividend and stock split history for Immuron Ltd (IMRN). It states that the company has distributed a total of $0.00 in dividends over the past five years and shows "No Data" for specific dividend dates. The article includes โฆ
This article details the shareholder structure of Immuron Ltd (IMRN), listing major individual and institutional holders as of recent reporting periods. It highlights the proportion of shares held by entities such as Morgan Stanley, Citadel Advisors, and XTX Markets, alongside a breakdown by shareholder โฆ
Immuron (NASDAQ: IMRN; ASX: IMC) announced that CEO Steven Lydeamore would present at a Kalkine Media Webinar on July 20, 2026, to discuss the company's developments in orally delivered targeted polyclonal antibodies for infectious diseases. Their flagship product, Travelan (IMMโ124E), is designed to prevent โฆ
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, announced that CEO Steven Lydeamore will present at the TechKnow Invest Roadshow in Melbourne on July 27, 2026. He will discuss the company's immunotherapy products, including its key commercial product Travelanยฎ for travelers' diarrhea โฆ
Immuron Limited announced that its CEO, Steven Lydeamore, will present at the TechKnow Invest Roadshow to highlight the company's orally delivered targeted polyclonal antibody platform. The presentation will cover its products like Travelan for travelers' diarrhea and IMM-529 for recurrent C. difficile infection, and โฆ
Immuron Limited (ASX: IMC; NASDAQ: IMRN) CEO Steven Lydeamore will present the company's strategic vision at a Kalkine Media Webinar on July 20, 2026, at 12:30 PM AEST. He is expected to discuss the company's clinical pipeline and commercial products, including its flagship traveler's โฆ
Immuron Limited reported FY26 global sales revenue of A$7.7 million, a 6% increase from the previous year, driven by strong growth in Australia and the US. The biopharmaceutical company is pursuing a strategic shift towards partnering its clinical assets, IMM-124E and IMM-529, to reduce โฆ
Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company, announced that CEO Steven Lydeamore will virtually present the company's strategy at the Kalkine Media Webinar on July 20, 2026, at 12:30 PM AEST. The presentation will cover its clinical pipeline and commercial products, โฆ
Immuron Limited reported a 6% increase in global revenue to AUD$7.7 million for FY26, driven by four consecutive quarters of sales growth, primarily stemming from strong performance in Australia. Australian sales rose 10% to AUD$5.8 million, while U.S. sales grew 7% in AUD terms โฆ
Immuron Limited reported continued sales growth for Travelanยฎ in FY26, with global sales reaching AUD$7.7 million, a 6% increase from the prior comparative period. Australia saw a 10% sales increase, driven by marketing and new store growth, while US sales increased by 7% in โฆ
Immuron Limited reported a 6% increase in global sales to AUD$7.7 million for FY26, driven by strong growth of its immune supplement Travelan in Australia and the U.S. Australian sales rose by 10% and U.S. sales by 7% (AUD) or 13% (USD), attributed to โฆ
Search by ticker symbol or company name and select a result to open its chart.
Start typing to find a stock or ETF.
Choose one or more countries for market search, or include every covered market.
Currently searching United States